Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1240716 | 0.94 | L3MBTL1 (0.56) | L3MBTL1HSD11B1PPARANPSR1NAAA | |
| SCHEMBL3194414 | 0.94 | L3MBTL1 (0.56) | L3MBTL1HSD11B1PPARANPSR1NAAA | |
| SCHEMBL2657530 | 0.86 | L3MBTL1 (0.40) | L3MBTL1 | |
| SCHEMBL2668517 | 0.83 | PYGL (0.41) | L3MBTL1PYGLNAAAKDM4EALDH1A1 | |
| SCHEMBL15358147 | 0.82 | L3MBTL1 (0.50) | L3MBTL1PPARAPYGL | |
| SCHEMBL12750822 | 0.82 | HSD11B1 (0.40) | L3MBTL1HSD11B1PPARAJAK2JAK1 | |
| SCHEMBL15779373 | 0.81 | L3MBTL1 (0.49) | L3MBTL1HSD11B1PPARANPSR1JAK2 | |
| SCHEMBL16527912 | 0.81 | L3MBTL1 (0.49) | L3MBTL1HSD11B1PPARAPYGLJAK2 | |
| SCHEMBL2657776 | 0.81 | KDM4E (0.41) | L3MBTL1PPARAKDM4EALDH1A1LMNA | |
| SCHEMBL6987866 | 0.77 | L3MBTL1 (0.59) | L3MBTL1PPARANPSR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586614-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-11-19 | — | — | US | disclosed |
| EP-1904467-B1 | Urea glucokinase activators | NOVO NORDISK AS (DK) | 2013-05-01 | — | — | EP | disclosed |
| US-8362049-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-8318778-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2012-11-27 | — | — | US | disclosed |
| US-20120165375-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2012-06-28 | — | — | US | disclosed |
| EP-2377856-A1 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2011-10-19 | — | — | EP | disclosed |
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
| US-20100041711-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-1904467-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105482-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | L3MBTL1 3946/4885HSD11B1 2916/4885PPARA 2109/4885 |
| US-20110077234-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | L3MBTL1 3946/4885HSD11B1 2916/4885PPARA 2109/4885 |
| US-20100041711-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | L3MBTL1 4720/4885HSD11B1 2923/4885PPARA 1441/4885 |
| US-20120165375-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | L3MBTL1 4720/4885HSD11B1 2923/4885PPARA 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.